<DOC>
	<DOCNO>NCT01341080</DOCNO>
	<brief_summary>The purpose study determine varenicline effective improve gait balance impairment patient Parkinson disease .</brief_summary>
	<brief_title>Varenicline Gait Balance Impairment Parkinson Disease</brief_title>
	<detailed_description>Parkinson disease ( PD ) clinical entity characterize bradykinesia , rigidity , tremor , postural instability . Current treatment primarily focus replacement dopamine compensate degeneration substantia nigra par compacta dopaminergic neuronal population . Though dopamine treat many motor symptom PD , postural instability ( often lead fall ) typically least responsive therapy . More recently , degeneration cholinergic system arise pedunculopontine nucleus ( PPN ) brainstem implicate gait dysfunction PD . Striatal cholinergic input supply PPN via intralaminar complex thalamus direct input . The primary subtypes cholinergic receptor present striatum nicotinic include α4β2 , α6β2 , α7 receptor . Varenicline ( Chantix ) novel partial α4β2 agonist full α7 agonist develop aid smoking cessation show initial study improve imbalance patient inherit spinocerebellar ataxia . The unique method action varenicline may make ideal drug treatment balance impairment PD .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Subjects diagnose Parkinson Disease ( PD ) UK Brain Bank criterion . Subjects least stage 2 Hoehn Yahr stag system PD history least 1 fall near fall last 6 month Subjects must stable medication regimen . All subject age 40 attempt exclude inherit form parkinsonism . Serum creatine kinase , complete metabolic panel , complete blood count , liver function test , renal function test , platelet EKG within normal limit ( result obtain primary care physician date within past 6 month obtain screen visit ) . Hoehn Yahr stage V subject . Subjects history major psychiatric disorder , deep brain stimulation surgery , recent cerebral trauma , cardiac arrhythmia , renal insufficiency . A cardiovascular procedure last 5 year ( eg , percutaneous transluminal coronary angioplasty ) cardiovascular instability ( include myocardial infarction unstable angina ) . Other cardiovascular exclusion include uncontrolled hypertension , significant neurological sequela cerebrovascular disease , peripheral vascular disease prior amputation , severe congestive heart failure ( New York Heart Association class III IV ) . Concurrent treatment MAOIs , bupropion ( Wellbutrin ) , nicotine patch . Dementia psychiatric illness prevents patient give informed consent ( Folstein Mini Mental Status Exam score less 25 ) . Concurrent treatment trihexyphenidyl ( Artane ) benztropine mesylate ( Cogentin ) . Significant degree dysphagia , history . Legal incapacity limit legal capacity . Presence severe renal disease ( BUN 50 % great normal creatinine clearance &lt; 60 mL/min ) hepatic disease . Abnormal creatine kinase and/or platelet count past 6 month ( determine lab report obtain primary care physician conduct baseline ) . Use varenicline within previous 30 day . Women childbearing potential pregnant time screen use adequate protection participation study . Allergy/sensitivity drug formulation . Concurrent participation another clinical study . Active substance tobacco use dependence . Moderate severe chronic obstructive pulmonary disease . Serious illness ( require systemic treatment/or hospitalization ) subject either complete therapy clinically stable therapy , opinion site investigator , least 60 day prior study entry . Inability unwillingness subject legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Balance</keyword>
	<keyword>Postural impairment</keyword>
	<keyword>Falls</keyword>
	<keyword>Parkinson Disease</keyword>
</DOC>